ANI Pharmaceuticals (NASDAQ:ANIP) Issues FY 2025 Earnings Guidance

Key Points

• ANI Pharmaceuticals has updated its FY 2025 earnings guidance, projecting earnings per share between $6.980 and $7.350, surpassing the consensus estimate of $6.523.
• The company forecasts revenue of $818.0 million to $843.0 million, which exceeds the consensus revenue estimate of $788.1 million.
• Brokerage firm Wall Street Zen upgraded ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating, while the average analyst rating for the stock is now a "Buy" with a consensus price target of $84.75.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) issued an update on its FY 2025 earnings guidance on Sunday morning. The company provided EPS guidance of 6.980-7.350 for the period, compared to the consensus EPS estimate of 6.523. The company issued revenue guidance of $818.0 million-$843.0 million, compared to the consensus revenue estimate of $788.1 million.

ANI Pharmaceuticals Trading Up 0.3%

Shares of ANIP stock traded up $0.30 on Friday, hitting $91.44. The stock had a trading volume of 150,152 shares, compared to its average volume of 371,880. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $92.53. The company has a fifty day moving average price of $70.06 and a two-hundred day moving average price of $65.69. The firm has a market cap of $1.98 billion, a P/E ratio of -118.57 and a beta of 0.61.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.42 by $0.38. The firm had revenue of $211.37 million for the quarter, compared to the consensus estimate of $187.18 million. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The business's quarterly revenue was up 53.2% on a year-over-year basis. During the same period last year, the company posted $1.02 EPS. As a group, analysts forecast that ANI Pharmaceuticals will post 3.86 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on ANIP. Piper Sandler reissued an "overweight" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Truist Financial lifted their price target on ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a "hold" rating in a report on Monday, August 11th. Guggenheim reaffirmed a "buy" rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. Wall Street Zen upgraded ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 16th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $93.00 price objective (up from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, ANI Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $84.75.

Insider Activity at ANI Pharmaceuticals

In related news, SVP Chad Gassert sold 20,000 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $86.97, for a total transaction of $1,739,400.00. Following the sale, the senior vice president owned 173,226 shares of the company's stock, valued at $15,065,465.22. This represents a 10.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Nikhil Lalwani sold 56,960 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $85.93, for a total value of $4,894,572.80. Following the completion of the transaction, the chief executive officer directly owned 411,219 shares of the company's stock, valued at $35,336,048.67. This represents a 12.17% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 301,247 shares of company stock valued at $26,264,427. 11.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Rubric Capital Management LP lifted its stake in ANI Pharmaceuticals by 354.7% in the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company's stock valued at $16,813,000 after buying an additional 200,998 shares during the period. First Trust Advisors LP grew its position in shares of ANI Pharmaceuticals by 128.1% during the 2nd quarter. First Trust Advisors LP now owns 81,214 shares of the specialty pharmaceutical company's stock worth $5,299,000 after buying an additional 45,613 shares during the period. PDT Partners LLC bought a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at $2,965,000. Bank of America Corp DE lifted its position in shares of ANI Pharmaceuticals by 32.0% during the 2nd quarter. Bank of America Corp DE now owns 185,465 shares of the specialty pharmaceutical company's stock valued at $12,102,000 after acquiring an additional 44,916 shares during the period. Finally, Qube Research & Technologies Ltd boosted its stake in ANI Pharmaceuticals by 113.4% during the second quarter. Qube Research & Technologies Ltd now owns 76,185 shares of the specialty pharmaceutical company's stock worth $4,971,000 after acquiring an additional 40,481 shares in the last quarter. Institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.